{"id":6658,"date":"2024-11-21T16:01:35","date_gmt":"2024-11-21T15:01:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6658"},"modified":"2025-04-28T21:27:44","modified_gmt":"2025-04-28T19:27:44","slug":"second-line-tislelizumab-versus-chemotherapy-in-japanese-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-subgroup-analysis-from-rationale-302","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/second-line-tislelizumab-versus-chemotherapy-in-japanese-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-subgroup-analysis-from-rationale-302\/","title":{"rendered":"Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6658","publication","type-publication","status-publish","hentry","disease_state-esophageal-squamous-cell-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6658"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}